CG Oncology, Inc. Annual Report - Fiscal Year 2025 Review

Considering an investment in CG Oncology, Inc.? This comprehensive review distills their fiscal year 2025 performance from their latest 10-K filing. We'll explore their achievements, financial health, and future prospects, providing the insights you need to assess their investment potential.

What does this company do and how did they perform this year?

CG Oncology is a clinical-stage biotechnology company that develops innovative oncolytic immunotherapies to fight cancer. Their leading product candidate, cretostimogene grenadenorepvec (cretostimogene), is an investigational oncolytic adenovirus. This therapy is designed to selectively infect and destroy cancer cells while also boosting the body's immune response against tumors. The company primarily targets non-muscle invasive bladder cancer (NMIBC), a form of bladder cancer that has not spread into the bladder muscle.

In 2025, CG Oncology significantly advanced cretostimogene. A major achievement was completing patient enrollment for their pivotal Phase 3 BOND-003 trial. This trial focuses on high-risk NMIBC patients who have not responded to BCG therapy, marking a crucial step toward potential regulatory submission. The company also explored a simplified, two-step administration process for cretostimogene, with promising initial data indicating comparable effectiveness and greater patient convenience.

Financial performance - revenue, profit, growth metrics

In fiscal year 2025, CG Oncology generated total revenue of $5.5 million, primarily from collaboration agreements and research grants. As a clinical-stage biotechnology company, it is not yet profitable. The company reported a net loss of $185.2 million for the year, an increase from $140.1 million in 2024. This larger loss reflects substantial investment in research and development (R&D), which reached $160.8 million in 2025, up from $125.5 million in the previous year. This increase was primarily due to advancing the BOND-003 trial and expanding its pipeline. General and administrative expenses totaled $35.0 million. The company continues to prioritize clinical development over immediate commercial revenue.

Major wins and challenges this year

This year brought both significant achievements and notable hurdles for CG Oncology.

Major Wins:

• Phase 3 BOND-003 Trial Enrollment Completed: This crucial milestone reduces development risk and prepares the path for data readout and potential regulatory submission.
• Positive Interim Data for Simplified Administration: Early results suggest an improved patient experience and could lead to wider adoption after approval.
• Clinical Pipeline Expansion: The company initiated a Phase 1 trial for cretostimogene combined with a checkpoint inhibitor for another solid tumor, expanding its pipeline beyond NMIBC.

Challenges:

• Rising R&D Expenses: While essential for progress, the substantial increase in R&D costs contributed to a larger net loss.
• Regulatory Uncertainty: Like all investigational drugs, cretostimogene faces no guarantee of FDA approval, and the timeline remains unpredictable.
• Competitive Landscape: The NMIBC market is dynamic, with new therapies and ongoing clinical trials from competitors presenting a challenge.

Financial health - cash, debt, liquidity

As of December 31, 2025, CG Oncology held a strong cash position, with $320.0 million in cash, cash equivalents, and marketable securities. This total includes approximately $150 million net from a successful follow-on public offering completed in mid-2025. The company reported no significant long-term debt, reflecting a healthy balance sheet. Management estimates these resources can fund operations into late 2027, covering the anticipated Biologics License Application (BLA) filing for cretostimogene and initial commercialization efforts.

The company's market capitalization, based on its public float (shares held by non-affiliates), stood at approximately $1.7 billion as of June 30, 2025. With 84.4 million shares outstanding as of February 25, 2026, CG Oncology qualifies as a 'well-known seasoned issuer' and a 'large accelerated filer.' These classifications signify a company with substantial market value and a consistent record of timely, comprehensive SEC filings, generally indicating a more established public presence.

Key risks that could hurt the stock price

Investing in CG Oncology involves inherent risks typical of clinical-stage biotechnology companies:

• Clinical Trial Outcomes: Cretostimogene's success hinges on positive data from the BOND-003 trial. Negative or inconclusive results would severely impact the company.
• Regulatory Approval: Even with positive trial data, the FDA or other regulatory bodies may not approve cretostimogene, and the approval process is often lengthy and complex.
• Commercialization Challenges: If approved, the company faces risks related to market acceptance, manufacturing scale-up, pricing and reimbursement negotiations, and competition.
• Intellectual Property: Protecting its patents and proprietary technology is crucial for the company's long-term viability.
• Future Funding Needs: While currently well-funded, future capital raises may become necessary, potentially diluting existing shareholders.

Competitive positioning

CG Oncology develops cretostimogene for high-risk NMIBC, a market with significant unmet needs, especially for patients unresponsive to BCG. Key competitors include established pharmaceutical companies with existing or developing therapies, such as Merck (Keytruda), ImmunityBio (Anktiva), and Ferring Pharmaceuticals (Adstiladrin). Cretostimogene's unique oncolytic virus mechanism, which directly attacks cancer cells and stimulates a lasting immune response, differentiates it. The company aims to establish cretostimogene as a 'best-in-disease' option by leveraging its potential to directly destroy tumors and activate the immune system.

Leadership and strategy changes

The executive leadership team remained stable in 2025, with no significant changes announced. The company's core strategy focuses on:

1. Successfully bringing cretostimogene to market for NMIBC.
2. Expanding cretostimogene's potential into additional cancer indications through combination therapies.
3. Leveraging its oncolytic virus platform to develop new pipeline candidates.
4. Exploring strategic partnerships to maximize product reach and development.

Future outlook

CG Oncology's future largely depends on cretostimogene's successful development and commercialization. Key milestones expected in 2026 include:

• Top-line data readout from the Phase 3 BOND-003 trial in mid-2026.
• Potential Biologics License Application (BLA) submission to the FDA in late 2026 or early 2027, assuming positive data.
• Continued progress in its expanded pipeline and combination studies.

While optimistic about cretostimogene's potential to significantly improve outcomes for bladder cancer patients, the company cautions that these are forward-looking statements subject to inherent risks and uncertainties.

Market trends and regulatory changes affecting them

The oncology market continues its strong growth, fueled by an aging population and advances in personalized medicine and immunotherapy. The NMIBC market, in particular, is innovating, with a growing focus on bladder-sparing therapies and treatments for BCG-unresponsive patients. Regulatory bodies like the FDA are increasingly open to accelerated approval pathways for therapies addressing high unmet medical needs, potentially benefiting cretostimogene. However, evolving drug pricing pressures and global reimbursement policies significantly impact market access and profitability for all pharmaceutical companies, including CG Oncology.